Among patented mAbs directed towards EGFR that are not yet in clinical use, one has been proposed for use in ovarian cancer (patent number WO2005010151); however, as it is directed against deletion mutants of EGFR (particularly EGFRvIII), its use in ovarian cancer is likely to be limited. The gene discussed is EGFR; the disease is ovarian cancer.